tailieunhanh - A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: Prolongation of prostate-specific antigen doubling time

Cancer vaccine is one of the attractive treatment modalities for patients with castration-resistant prostate cancer (CRPC). However, because of delayed immune responses, its clinical benefits, besides for overall survival (OS), are not well captured by the World Health Organization (WHO) and Response Evaluation Criteria in Solid Tumors (RECIST) criteria. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN